CNCE Concert Pharmaceuticals Inc.

14.99
+0.11  (1%)
Previous Close 14.88
Open 15.25
Price To book 5.28
Market Cap 340080933
Shares 22,687,187
Volume 622,683
Short Ratio 5.30
Av. Daily Volume 128,616

SEC filingsSee all SEC filings

  1. 8-K - Current report 171075093
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171013208
  3. 8-K - Current report 171013199
  4. 8-K - Current report 17980471
  5. 8-K - Current report 17956342

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 clinical hold placed May 17, 2017 lifted July 10, 2017. Trial completion due 2H 2018.
CTP-543
Alopecia areata
Phase 3 initiated December 2015. Trial to be completed 3Q 2018
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3 planned. Needs partner
CTP-499
Diabetic Kidney Disease

Latest News

  1. Concert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference
  2. Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  3. Concert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : August 23, 2017
  4. Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media
  5. Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 22, 2017
  6. Edited Transcript of CNCE earnings conference call or presentation 8-Aug-17 12:30pm GMT
  7. Concert reports 2Q loss
  8. Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update
  9. Investor Network: Concert Pharmaceuticals, Inc. to Host Earnings Call
  10. Concert Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
  11. Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656
  12. Concert Pharmaceuticals Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex
  13. Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : CNCE-US : July 18, 2017
  14. FDA lifts hold on Concert Pharma's study testing hair loss drug
  15. FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543
  16. Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : July 7, 2017
  17. Concert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : June 26, 2017
  18. Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : CNCE-US : June 23, 2017
  19. Concert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital

SEC Filings

  1. 8-K - Current report 171075093
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171013208
  3. 8-K - Current report 171013199
  4. 8-K - Current report 17980471
  5. 8-K - Current report 17956342
  6. 8-K - Current report 17917476
  7. 8-K - Current report 17904575
  8. 8-K - Current report 17875706
  9. 8-K - Current report 17870304
  10. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17859797